Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses

被引:27
|
作者
Chow, Edwin Chiu Yuen [1 ,2 ]
Talattof, Arjang [1 ,2 ]
Tsakalozou, Eleftheria [1 ,2 ]
Fan, Jianghong [1 ,2 ]
Zhao, Liang [1 ,2 ]
Zhang, Xinyuan [1 ,2 ]
机构
[1] US FDA, Div Quantitat Methods & Modeling, Off Res & Stand, Off Gener Drugs, Silver Spring, MD 20993 USA
[2] 10903 New Hampshire Ave,Bldg 75,Room 4690, Silver Spring, MD 20993 USA
来源
AAPS JOURNAL | 2016年 / 18卷 / 06期
关键词
Biopharmaceutics Classification System (BCS); excipients; gastrointestinal transporters; oral drug absorption; PBPK modeling; BIOPHARMACEUTICS CLASSIFICATION-SYSTEM; PEPTIDE TRANSPORTER PEPT1; COMMONLY USED EXCIPIENTS; P-GLYCOPROTEIN; CREMOPHOR EL; CACO-2; CELLS; BIOAVAILABILITY; PERMEABILITY; SURFACTANTS; METABOLISM;
D O I
10.1208/s12248-016-9964-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug solubility, effective permeability, and intestinal metabolism and transport are parameters that govern intestinal bioavailability and oral absorption. However, excipients may affect the systemic bioavailability of a drug by altering these parameters. Thus, parameter sensitivity analyses using physiologically based pharmacokinetic (PBPK) models were performed to examine the potential impact of excipients on oral drug absorption of different Biopharmaceutics Classification System (BCS) class drugs. The simulation results showed that changes in solubility had minimal impact on C-max and AUC(0-t) of investigated BCS class 1 and 3 drugs. Changes in passive permeability altered C-max more than AUC(0-t) for BCS class 1 drugs but were variable and drug-specific across different BCS class 2 and 3 drugs. Depending on the drug compounds for BCS class 1 and 2 drugs, changes in intestinal metabolic activity altered C-max and AUC(0-t). Reducing or increasing influx and efflux transporter activity might likely affect C-max and AUC(0-t) of BCS class 2 and 3 drugs, but the magnitude may be drug dependent. Changes in passive permeability and/or transporter activity for BCS class 2 and 3 drugs might also have a significant impact on fraction absorbed and systemic bioavailability while changes in intestinal metabolic activity may have an impact on gut and systemic bioavailability. Overall, we demonstrate that PBPK modeling can be used routinely to examine sensitivity of bioavailability based on physiochemical and physiological factors and subsequently assess whether biowaiver requirements need consideration of excipient effects for immediate release oral solid dosage forms.
引用
收藏
页码:1500 / 1511
页数:12
相关论文
共 50 条
  • [31] Predicting the Disposition of the Antimalarial Drug Artesunate and Its Active Metabolite Dihydroartemisinin Using Physiologically Based Pharmacokinetic Modeling
    Arey, Ryan
    Reisfeld, Brad
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (03)
  • [32] Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches
    Guo, Yingying
    Chu, Xiaoyan
    Parrott, Neil J.
    Brouwer, Kim L. R.
    Hsu, Vicky
    Nagar, Swati
    Matsson, Par
    Sharma, Pradeep
    Snoeys, Jan
    Sugiyama, Yuichi
    Tatosian, Daniel
    Unadkat, Jashvant D.
    Huang, Shiew-Mei
    Galetin, Aleksandra
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (05) : 865 - 889
  • [33] Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug
    Salem, Farzaneh
    Nimavardi, Ali
    Mudunuru, Jennypher
    Tompson, Debra
    Bloomer, Jackie
    Turner, David B.
    Taskar, Kunal S.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (06): : 808 - 820
  • [34] Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption
    Willmann, Stefan
    Edginton, Andrea N.
    Kleine-Besten, Marcus
    Jantratid, Ekarat
    Thelen, Kirstin
    Dressman, Jennifer B.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2009, 61 (07) : 891 - 899
  • [35] Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice
    Grillo, Joseph A.
    Zhao, Ping
    Bullock, Julie
    Booth, Brian P.
    Lu, Min
    Robie-Suh, Kathy
    Berglund, Eva Gil
    Pang, K. Sandy
    Rahman, Atiqur
    Zhang, Lei
    Lesko, Lawrence J.
    Huang, Shiew-Mei
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2012, 33 (02) : 99 - 110
  • [36] Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions With Ethionamide Involving Impact of Genetic Polymorphism on FMO3
    Phuong Thi Thu Nguyen
    Parvez, Md Masud
    Kim, Min Jung
    Yoo, Sung Eun
    Ahn, Sangzin
    Ghim, Jong-Lyul
    Shin, Jae-Gook
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (06) : 880 - 889
  • [37] Simulation of oral absorption from non-bioequivalent dosage forms of the salt of raltegravir, a poorly soluble acidic drug, using a physiologically based biopharmaceutical modeling (PBBM) approach
    Komasaka, Takao
    Dressman, Jennifer
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 157
  • [38] Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling
    Yao, Yoshiaki
    Toshimoto, Kota
    Kim, Soo-Jin
    Yoshikado, Takashi
    Sugiyama, Yuichi
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (07) : 924 - 933
  • [39] Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling
    Rajoli, Rajith K. R.
    Curley, Paul
    Chiong, Justin
    Back, David
    Flexner, Charles
    Owen, Andrew
    Siccardi, Marco
    JOURNAL OF INFECTIOUS DISEASES, 2019, 219 (11) : 1735 - 1742
  • [40] Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity
    Lu Gaohua
    Miao, Xiusheng
    Liu Dou
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (09) : 1103 - 1124